Moderna (MRNA) Total Current Liabilities (2017 - 2026)

Moderna (MRNA) has reported Total Current Liabilities for 10 consecutive years, with $2.5 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 61.2% year-over-year to $2.5 billion in Q2 2026; TTM through Jun 2026 was $2.5 billion, a 61.2% increase from a year earlier, with the FY2025 full-year figure at $2.0 billion, down 9.93% from the prior year.
• Total Current Liabilities was $2.5 billion for Q2 2026 at Moderna, up from $2.4 billion in the prior quarter.
• Over five years, Total Current Liabilities peaked at $9.2 billion in Q1 2022 and troughed at $1.6 billion in Q2 2025.
• A 5-year average of $3.5 billion and a median of $2.5 billion in 2026 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities slumped 62.12% in 2023 and jumped 61.2% in 2026, its largest moves.
• Over 5 years, Total Current Liabilities stood at $4.9 billion in 2022, then sank by 38.76% to $3.0 billion in 2023, then declined by 26.83% to $2.2 billion in 2024, then declined by 9.93% to $2.0 billion in 2025, then increased by 27.53% to $2.5 billion in 2026.
• The last three Total Current Liabilities figures came in at $2.5 billion (Q2 2026), $2.4 billion (Q1 2026), and $2.0 billion (Q4 2025), per Business Quant data.